Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Pietras

Psychiatry West Palm Beach, FL Medical Doctor

NPI 1912346123 CMS profile 222348

2151 45Th St Ste 210, West Palm Beach, FL 33407

Open in the dashboard

General payments

$3,698

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Pietras of West Palm Beach, FL is reported in the CMS Open Payments database as having received $3,698 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,539 52
2023 General $261 3
2021 General $310 12
2020 General $490 15
2019 General $1,098 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Pietras
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Daniel Pietras were reported at $1,539. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Daniel Pietras Psychiatry median Middle half National median
2019 $1,098 $184 $59–$605 $163
2020 $490 $119 $36–$372 $114
2021 $310 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $261 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $1,539 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $626 15 payments
  2. Janssen Pharmaceuticals, Inc $611 16 payments
  3. Alkermes, Inc. $350 13 payments
  4. Allergan Inc. $349 7 payments
  5. Otsuka America Pharmaceutical, Inc. $348 10 payments
  6. ITI, Inc. $216 6 payments
  7. Sunovion Pharmaceuticals Inc. $214 15 payments
  8. Neurocrine Biosciences, Inc. $214 6 payments
  9. E.R. Squibb & Sons, L.L.C. $194 2 payments
  10. Axsome Therapeutics, Inc. $168 4 payments
  11. Other $406 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,621 114 payments
  2. Travel and Lodging $72 1 payment
  3. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. SPRAVATO $528 12 payments
  2. VRAYLAR $414 10 payments
  3. ARISTADA Cns $319 11 payments
  4. ARISTADA Cns $319 11 payments
  5. ARISTADA Cns $319 11 payments
  6. ARISTADA Cns $319 11 payments
  7. AUSTEDO $300 6 payments
  8. ABILIFY MAINTENA $272 8 payments
  9. LATUDA $214 15 payments
  10. Austedo XR $207 7 payments
  11. Other $1,925 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

721

Median for Psychiatry & Neurology: 100

Drug cost

$293,458

Median for Psychiatry & Neurology: $2,986

Branded share of claims

29.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 21 $136,416
Invega Sustenna Paliperidone Palmitate Brand 17 $60,393
Vraylar Cariprazine Hcl Brand 20 $27,020
Lybalvi Olanzapine/Samidorphan Malate Brand 13 $19,794
Caplyta Lumateperone Tosylate Brand 12 $18,759
Paliperidone Er Paliperidone Brand 40 $9,082
Trintellix Vortioxetine Hydrobromide Brand 15 $7,939
Aripiprazole Generic 22 $3,018
Clozapine Generic 37 $2,453
Divalproex Sodium Er Divalproex Sodium Brand 24 $1,173

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record